LASIK vs SMILE vs ICL: Which Vision Correction Is Right for You?

Published: June 2026

At some point in the journey toward glasses-free vision, most people face the same three options on a consultant's whiteboard. LASIK has thirty years of data behind it and more than 40 million procedures performed globally — one of the most studied elective procedures in medicine. SMILE arrived as a flapless refinement and has earned a specific following among patients with dry eyes and active lifestyles. ICL — an implanted lens rather than a laser procedure — has been gaining ground rapidly, particularly for patients with high prescriptions or corneas that make laser unsafe.

None of the three is universally best. Each occupies a clearly defined clinical niche, and the overlap between them is smaller than most comparison pages suggest. This guide gives you a genuinely useful framework — based on clinical evidence, real outcome data, and a clear decision map — for understanding which one is right for your specific eyes.

The one-line difference

LASIK: a thin flap is created on the corneal surface, an excimer laser reshapes the tissue beneath it, and the flap is repositioned. Permanent corneal change. Takes about 15 minutes per eye.

SMILE: no flap. A femtosecond laser creates a small disc of corneal tissue (a lenticule) entirely inside the cornea, which is then removed through a 2–3mm keyhole incision. Permanent corneal change. Takes about 20 minutes per eye.

ICL (Implantable Collamer Lens): no laser on the cornea at all. A small, flexible lens made from biocompatible collamer is implanted through a 3mm incision between the iris and the eye's natural lens. The cornea is untouched. Reversible. Takes about 15–20 minutes per eye.

All three are performed under topical anaesthetic drops as day procedures. All three achieve lasting vision correction. What differs is the mechanism, the recovery profile, who is suitable, and the risk trade-offs.

How they compare — side by side

When LASIK is the right choice

LASIK is still the world's most commonly performed refractive surgery, and for good reason. The track record is exceptional: LASIK has a 96–98% success rate globally, with most patients achieving 20/20 vision or better. Wavefront-guided and topography-guided systems — particularly Contoura Vision, which maps 22,000 individual corneal reference points — have pushed outcomes beyond simple prescription correction into high-order aberration management. FDA studies for Contoura guidance show 96% patient satisfaction and over 90% achieving 20/20 or better.

Recovery is LASIK's headline advantage. Most patients wake up the morning after surgery with dramatically improved vision. The vast majority return to desk work and normal activities within 24–48 hours. The procedure is the most economical of the three options and has the widest treatment range — it is one of the few refractive procedures that corrects hyperopia (long-sightedness) as well as myopia and astigmatism.

LASIK is the right choice when: your prescription falls within the treatable range (typically up to around −10 diopters of myopia), your corneas are adequately thick and healthy, you have no significant pre-existing dry eye, and you want the fastest recovery at the most accessible price. It is the default recommendation for the majority of suitable patients seeking vision correction.

Where LASIK falls short: the corneal flap — created by a femtosecond laser in modern bladeless LASIK — partially severs the corneal nerves that regulate tear production. For most patients, the resulting mild dry eye resolves within three to six months. For patients who already have moderate to severe dry eye before surgery, LASIK can make it meaningfully worse. The flap also remains a minor structural consideration for patients in high-impact contact sports.

For the full LASIK procedure guide, techniques (Femto, Contoura, SILK) and India costs, see our LASIK eye surgery in India page.

When SMILE has the edge

SMILE — Small Incision Lenticule Extraction — takes the laser vision correction principle and removes the flap entirely. A femtosecond laser creates a precisely shaped lenticule within the body of the cornea, which is then extracted through a 2–3mm incision. Because the corneal surface is largely undisturbed, the critical nerves that regulate tear production are largely preserved.

This is SMILE's defining clinical advantage: it is significantly less disruptive to the corneal tear film than flap-based LASIK. Multiple studies confirm that post-operative dry eye symptoms are lower in frequency and severity with SMILE than with standard LASIK. For patients who already have mild dry eye, or who work in dry environments, or who use screens extensively, SMILE is the more appropriate laser choice.

The Nethradhama Superspeciality Eye Hospital in Bengaluru published a matched comparison of SMILE, femto-LASIK and toric ICL for myopic astigmatism. At one year, 97% of SMILE eyes achieved 20/20 or better, compared to 90% for femto-LASIK and 93% for toric ICL. SMILE also offered better preservation of corneal biomechanical integrity — the structural stiffness of the cornea — which reduces the theoretical risk of progressive corneal thinning (ectasia) over the long term. SMILE PRO, the latest generation using the VisuMax 800 platform, delivers the lenticule cut at higher speed with improved precision.

SMILE is the right choice when: you are myopic (with or without mild astigmatism), you have borderline dry eye or a history of dry eye symptoms, you participate in contact sports or have an active lifestyle where avoiding a corneal flap is preferable, or you simply prefer the flapless approach for peace of mind.

Where SMILE has limits: SMILE does not currently correct hyperopia — it is approved for myopia and mild to moderate astigmatism only. For patients with significant hyperopia, LASIK or ICL remains necessary. SMILE's prescription range is also somewhat more conservative than LASIK at the extremes. And for astigmatism correction at higher levels, the precision of toric ICL may be preferred.

The newest SILK (Small Incision Lenticule Keratectomy) platforms represent the next evolution of flapless lenticule extraction — the latest generation available in India at the time of writing.

When ICL is the safer, sharper option

The EVO ICL (Implantable Collamer Lens) represents a fundamentally different approach to vision correction: rather than changing the cornea's shape, a thin, flexible lens is placed inside the eye between the iris and the natural crystalline lens. The cornea is not cut, not ablated and not thinned — making ICL genuinely independent of corneal anatomy.

The clinical data on EVO ICL outcomes are compelling. In the FDA premarket approval trial for EVO ICL, 94.5% of treated eyes achieved 20/20 or better uncorrected visual acuity — outperforming SMILE (84.2%), topography-guided LASIK (88.9%) and wavefront-guided LASIK (82.6%) in comparative FDA approval datasets. Equally striking: 56.0% of EVO ICL eyes gained one or more lines of best-corrected visual acuity after the procedure — meaning many patients saw better than they ever had with glasses. No eye lost more than one line of vision at any point through six months in the same study.

A four-year comparative study between SMILE and EVO ICL for high myopia (mean prescription around −8.5D) published in BMC Ophthalmology found that both procedures delivered comparable safety and efficacy at four years, with safety indices of 1.15 (SMILE) and 1.22 (ICL) and efficacy indices of 0.97 vs 0.96. Both had low complication rates, with halos as the most reported visual disturbance in both groups.

For patients with very high myopia — prescriptions beyond approximately −10 diopters — laser surgery becomes limited by the amount of corneal tissue available for safe ablation. ICL has no such constraint. The EVO ICL is approved for myopia up to −20 diopters and astigmatism up to 6 diopters with the toric version, making it the only viable surgical option for many high-myopia patients. It also delivers objectively superior visual quality at extreme prescriptions, with less spherical aberration than achievable with laser correction at the same power.

ICL is the right choice when: your prescription is very high (beyond roughly −10D of myopia or with significant astigmatism); your corneas are too thin for safe laser correction; you have moderate-to-severe dry eye that laser would worsen; you want a reversible option (the lens can be removed or replaced if needed); or you simply want the best possible optical quality at any prescription level.

The reversibility point needs honest framing: ICL's reversibility is a genuine advantage — no other common refractive procedure offers it — but removal is still intraocular surgery. One clinical ophthalmology commentator noted in Optometry Times (March 2026): "Yes, ICLs are technically 'removable', and this narrative is often touted online, but we should not trivialise this — it still involves intraocular surgery." Removal is uncommon and straightforward in experienced hands, but patients should understand it is not as simple as removing a contact lens.

Honest ICL risks: as with all intraocular surgery, ICL carries risks that laser does not. These include — at low frequency — the possibility of elevated intraocular pressure, cataract formation (particularly if the lens is incorrectly sized), or endothelial cell loss over very long periods. The EVO design has significantly reduced these risks compared to earlier ICL models by eliminating the need for peripheral iridotomy and improving aqueous flow. Thorough pre-operative assessment — including anterior chamber depth measurement and endothelial cell count — determines whether your eye anatomy is suitable.

ICL surgery in India costs ₹75,000–₹1,60,000 per eye, a fraction of the USD 4,000–7,000 per eye charged in the United States for the same STAAR EVO lens.

Which should you choose?

The question looks like a preference question. It is actually an anatomy question. The right procedure is determined by your corneal thickness, your prescription power and the condition of your tear film — not by which procedure has the best marketing or the most impressive name.

Choose LASIK if: your prescription is low to moderate, your corneas are healthy and adequately thick, you don't have meaningful dry eye, and you want the fastest recovery at the best value. Add Contoura Vision if optical quality is your priority; add SILK for the newest flapless platform.

Choose SMILE if: you are myopic (not hyperopic), you value the flapless approach — whether for dry eye, lifestyle or peace of mind — and the SMILE prescription range covers your correction. Expect marginally slower initial recovery than LASIK but comparable outcomes by the end of the first month.

Choose ICL if: your prescription is high (beyond ~−10D), your corneas are thin, you have dry eye that contraindicates laser, or you want a reversible option with the best possible visual quality at your prescription level.

The practical starting point: a corneal topography scan and measurement of your corneal thickness — both done in a standard pre-operative assessment — immediately clarifies whether your corneas are suitable for laser correction. If they are, the choice between LASIK and SMILE is a lifestyle and dry-eye discussion. If they are not, ICL is your pathway. Send us your current prescription on WhatsApp and we'll tell you, without obligation, which procedures your prescription makes you likely suitable for — before you book anything.

Cost in India — LASIK vs SMILE vs ICL

India offers all three procedures at 60–80% below the cost of equivalent surgery in the US, UK or UAE. The same STAAR EVO ICL, the same Alcon WaveLight or ZEISS laser platforms, the same surgical expertise — at a structurally different cost.

Indicative 2026 price ranges at accredited private hospitals in India. Your confirmed all-inclusive quote from MediGoCare specifies the exact technique and lens.

For international patients, the arithmetic is straightforward. A patient from the UK considering SMILE for both eyes — which might cost £5,000–£7,000 in London — can have the same SMILE Pro procedure at a top Delhi NCR refractive centre for around ₹1,80,000–₹3,00,000 (~£1,700–£2,800), and still spend less than the UK surgery cost alone even after flights and accommodation.

For the full price guide across all eye procedures, see our eye surgery cost in India guide. For detailed LASIK technique comparisons, costs and the complete international patient guide, see our LASIK eye surgery in India page.

Frequently asked questions

Medical disclaimer: This article is for general information and educational purposes and does not constitute medical advice. Suitability for any vision correction procedure must be determined by a qualified ophthalmologist after a full pre-operative assessment. Clinical outcome statistics are sourced from US FDA premarket approval studies, peer-reviewed literature including PMC publications, and published clinical series. Cost figures are indicative 2026 estimates. Last reviewed: June 2026.